Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Gandhi, Isha

  • Google
  • 3
  • 56
  • 61

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (3/3 displayed)

  • 2020Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor28citations
  • 2020Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease4citations
  • 2020Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin29citations

Places of action

Chart of shared publication
Bachanova, Veronika
1 / 1 shared
Brunstein, Claudio G.
1 / 1 shared
Miller, Jeffrey S.
1 / 2 shared
Rashidi, Armin
2 / 3 shared
Ustun, Celalettin
1 / 1 shared
Slungaard, Arne
1 / 1 shared
Weisdorf, Daniel
1 / 1 shared
Warlick, Erica D.
1 / 1 shared
Macmillan, Margaret L.
2 / 2 shared
Blazar, Bruce R.
2 / 4 shared
Betts, Brian C.
2 / 2 shared
Shabaneh, Ashraf
1 / 1 shared
Vercellotti, Gregory M.
1 / 2 shared
Hoeschen, Andrea L.
1 / 1 shared
Jurdi, Najla El
1 / 1 shared
Cao, Qing
2 / 2 shared
He, Fiona
1 / 1 shared
Jacobson, Pamala Ann
1 / 1 shared
Arora, Mukta
1 / 1 shared
Panoskaltsis-Mortari, Angela
2 / 4 shared
Wagner, John E.
1 / 1 shared
Wang, Jinhua
1 / 4 shared
Gandhi, Parth
1 / 1 shared
Hoeschen, Andrea
1 / 1 shared
Khoruts, Alexander
1 / 1 shared
Weisdorf, Daniel J.
1 / 1 shared
Mosher, Wes
1 / 1 shared
Jurdi, Najla H. El
1 / 1 shared
Holtan, Shernan G.
1 / 1 shared
Chen, Chi
1 / 2 shared
Chart of publication period
2020

Co-Authors (by relevance)

  • Bachanova, Veronika
  • Brunstein, Claudio G.
  • Miller, Jeffrey S.
  • Rashidi, Armin
  • Ustun, Celalettin
  • Slungaard, Arne
  • Weisdorf, Daniel
  • Warlick, Erica D.
  • Macmillan, Margaret L.
  • Blazar, Bruce R.
  • Betts, Brian C.
  • Shabaneh, Ashraf
  • Vercellotti, Gregory M.
  • Hoeschen, Andrea L.
  • Jurdi, Najla El
  • Cao, Qing
  • He, Fiona
  • Jacobson, Pamala Ann
  • Arora, Mukta
  • Panoskaltsis-Mortari, Angela
  • Wagner, John E.
  • Wang, Jinhua
  • Gandhi, Parth
  • Hoeschen, Andrea
  • Khoruts, Alexander
  • Weisdorf, Daniel J.
  • Mosher, Wes
  • Jurdi, Najla H. El
  • Holtan, Shernan G.
  • Chen, Chi
OrganizationsLocationPeople

article

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

  • Aziz, Mina
  • Kitko, Carrie L.
  • Etra, Aaron M.
  • Young, Rachel
  • Defilipp, Zachariah
  • Gandhi, Isha
  • Merli, Pietro
  • Bunworasate, Udomsak
  • Rösler, Wolf
  • Holler, Ernst
  • Kowalyk, Steven M.
  • Ferrara, James L. M.
  • Nakamura, Ryotaro
  • Baez, Janna
  • Ayuk, Francis
  • Choe, Hannah K.
  • Morales, George
  • Sandhu, Karamjeet S.
  • Özbek, Umut
  • Reshef, Ran
  • Ben-David, Kaitlyn
  • Gergoudis, Stephanie C.
  • Srinagesh, Hrishikesh
  • Levine, John
  • Chen, Yi-Bin
  • Hogan, William J.
  • Kasikis, Stelios
Abstract

<jats:title>Abstract</jats:title><jats:p>Steroid-refractory (SR) acute graft-versus-host disease (GVHD) remains a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT), but its occurrence is not accurately predicted by pre-HCT clinical risk factors. The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP) identifies patients who are at high risk for developing SR GVHD as early as 7 days after HCT based on the extent of intestinal crypt damage as measured by the concentrations of 2 serum biomarkers, suppressor of tumorigenesis 2 and regenerating islet-derived 3α. We conducted a multicenter proof-of-concept “preemptive” treatment trial of α-1-antitrypsin (AAT), a serine protease inhibitor with demonstrated activity against GVHD, in patients at high risk for developing SR GVHD. Patients were eligible if they possessed a high-risk MAP on day 7 after HCT or, if initially low risk, became high risk on repeat testing at day 14. Thirty high-risk patients were treated with twice-weekly infusions of AAT for a total of 16 doses, and their outcomes were compared with 90 high-risk near-contemporaneous MAGIC control patients. AAT treatment was well tolerated with few toxicities, but it did not lower the incidence of SR GVHD compared with controls (20% vs 14%, P = .56). We conclude that real-time biomarker-based risk assignment is feasible early after allogeneic HCT but that this dose and schedule of AAT did not change the incidence of SR acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT03459040.</jats:p>

Topics
  • impedance spectroscopy
  • refractory